This recommendation is based on the inclusion criteria of the Destiny-GC-02 trial and the knowledge that loss of HER2 status occurs in approximately 30% of gastric cancers after first-line therapy with trastuzumab [62]. This evidence concerns the gene ERBB2 and gastric cancer.